Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adrecizumab during experimental endotoxemia in healthy volunteers
NL-OMON43006Phase 1Active, not recruiting
- Sponsor
- Adrenomed AG
- Start
- Jan 2017
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adrecizumab (4 arms), sponsored by Adrenomed AG. Primary endpoint: Safety and tolerability. Started Jan 2017; status: active, not recruiting.
02
Drugs
adrecizumab
Beyond the preview
Go deeper on NL-OMON43006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43006.